A new vaccine and treatment for Hepatitis B
Official title: Novel Hepatitis B Vaccine and Immunotherapy
Funded at Scripps Research Institute, the · NIH-11136655 · Data updated 2026-11-12
This study is testing a new mRNA vaccine and treatment to help people with Hepatitis B by boosting their immune system to fight the virus better, with the hope of finding a cure for the disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scripps Research Institute, the NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | August 21, 2024 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $883,119 |
| NIH project number | 1R56AI171444-01A1 |
| Project ID | NIH-11136655 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with chronic Hepatitis B infection.
✕Less likely to help
Patients who have already been cured of Hepatitis B or those without the infection may not benefit from this research.
What this research studies
This research focuses on developing a novel mRNA vaccine and immunotherapy to combat Hepatitis B virus (HBV), which affects over 250 million people globally. The approach aims to not only suppress the virus but also to enhance the body's immune response against it. Researchers will investigate the factors that hinder effective vaccine antigen expression and work on improving these antigens to elicit strong antibody and T cell responses. If successful, this could lead to a cure for HBV and pave the way for similar vaccines against other pathogens.
Why it matters
Potential benefit: If successful, this research could provide a potential cure for Hepatitis B, significantly improving the health outcomes for millions of infected individuals.
How similar studies have gone: Other research has shown promise with mRNA vaccine technology in combating various viral infections, indicating a potential for success in this novel approach.
Where this research is happening
-
Scripps Research Institute, the
La Jolla, United States Active
Researchers
- Principal investigator: Law, Mansun — Scripps Research Institute, the
- Study coordinator: Law, Mansun
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
HBV cure clues in people with and without HIV
This project studies how HBV-specific B and T cell responses relate to curing hepatitis B in people with and without HIV.
-
HBV cure factors in people with and without HIV
This project studies how HBV-specific immune cells behave during treatment and whether people with HIV respond differently than those without HIV.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.